论文部分内容阅读
目的观察重组干扰素α 2b(干扰能)治疗慢性乙型肝炎的疗效、影响疗效的因素和对长期预后的影响。方法88例慢性乙型肝炎病例配对分为治疗组和对照组各44例。治疗组用重组干扰素α 2b3×106U ,每周3次 ,皮下注射 ,疗程3个月 ,对照组不用抗病毒治疗。42例开放病例根据治疗剂量分为3×106U和6×106U2组,治疗方法为每周3次或隔日1次,深皮下或肌肉注射,疗程3个月。结果用重组干扰素α 2b治疗的全部病例在治疗完成时、随访6个月、1～7年的有效应答率(完全应答 +部分应答,分别为55.8 %、58.8 %、61.9 %、57.9 %、58.5 %、56.1 %、52.6 %、45.5 %和50.0 %)均显著高于对照组(分别为13.6 %、13.6 %、15.9 %、15.9 %、13.6 %、15.0 %、15.2 %、11.1 %和7.7 %),P<0.05或P<0.01。6×106 U和3×106 U治疗组间有效应答率差异无显著性(P>0.05)。中度慢性肝炎、治疗前ALT>100IU/L、病程短于3年、女性病人和治疗开始后有发热者的疗效较好(P<0.05)。治疗组的长期预后明显优于对照组(P<0.05),有效应答病例的长期预后显著优于无应答病例(P<0.05)。结论重组干扰素α 2b是一种肯定有效的抗乙型肝炎病毒药物。干扰素治疗可改善慢性乙型肝炎病人的长期预后。
Objective To observe the therapeutic effect of recombinant interferon α 2b (interfering energy) on chronic hepatitis B, the factors influencing the curative effect and its effect on long-term prognosis. Methods A total of 88 cases of chronic hepatitis B cases were divided into treatment group and control group, 44 cases each. Treatment group with recombinant interferon α 2b3 × 106U, 3 times a week, subcutaneous injection, treatment for 3 months, the control group without antiviral therapy. 42 cases of open cases were divided into 3 × 106U and 6 × 106U2 groups according to the therapeutic dose. The treatment was 3 times a week or every other day, and then injected subcutaneously or intramuscularly for 3 months. Results All cases treated with recombinant interferon α 2b had a response rate of 1 to 7 years (complete response + partial response, 55.8%, 58.8%, 61.9%, 57.9%, respectively) 58.5%, 56.1%, 52.6%, 45.5% and 50.0% respectively) were significantly higher than those in the control group (13.6%, 13.6%, 15.9%, 15.9%, 13.6%, 15.0%, 15.2%, 11.1% and 7.7% ), P <0.05 or P <0.01.6 × 106 U and 3 × 106 U treatment group no significant difference in the effective response rate (P> 0.05). Moderate chronic hepatitis, ALT> 100 IU / L before treatment, duration of less than 3 years, female patients and fever after treatment is better (P <0.05). The long-term prognosis of the treatment group was significantly better than that of the control group (P <0.05). The long-term prognosis of the effective response was significantly better than that of the non-response (P <0.05). Conclusion Recombinant IFNα 2b is a positive and effective anti-hepatitis B virus drug. Interferon therapy can improve the long-term prognosis of patients with chronic hepatitis B.